Biography:
Dr. Yanjing Zhu is a resident physician in Clinical Oncology at Fudan University Zhongshan Hospital, specializing in digestive system tumors. Her research centers on umor metabolism, immunotherapy, organoid models, and drug resistance mechanisms. She has published multiple first-author papers in high-impact journals such as Cell Reports Medicine and Hepatology, and leads two National Natural Science Foundation projects. Her work aims to advance precision oncology through translational research.
Targeting ATF3-mediated asparagine biosynthesis reverses acquired resistance to KRASG12C inhibitors